Current trends in natural products for the treatment and management of dementia: Computational to clinical studies

Neurosci Biobehav Rev. 2023 Apr;147:105106. doi: 10.1016/j.neubiorev.2023.105106. Epub 2023 Feb 23.


The number of preclinical and clinical studies evaluating natural products-based management of dementia has gradually increased, with an exponential rise in 2020 and 2021. Keeping this in mind, we examined current trends from 2016 to 2021 in order to assess the growth potential of natural products in the treatment of dementia. Publicly available literature was collected from various databases like PubMed and Google Scholar. Oxidative stress-related targets, NF-κB pathway, anti-tau aggregation, anti-AChE, and A-β aggregation were found to be common targets and pathways. A retrospective analysis of 33 antidementia natural compounds identified 125 sustainable resources distributed among 65 families, 39 orders, and 7 classes. We found that families such as Berberidaceae, Zingiberaceae, and Fabaceae, as well as orders such as Lamiales, Sapindales, and Myrtales, appear to be important and should be researched further for antidementia compounds. Moreover, some natural products, such as quercetin, curcumin, icariside II, berberine, and resveratrol, have a wide range of applications. Clinical studies and patents support the importance of dietary supplements and natural products, which we will also discuss. Finally, we conclude with the broad scope, future challenges, and opportunities for field researchers.

Keywords: Artificial intelligence; Deep machine learning; Dementia; Natural products; Treatment and management.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products* / therapeutic use
  • Curcumin*
  • Dementia* / drug therapy
  • Humans
  • Resveratrol
  • Retrospective Studies


  • Biological Products
  • Resveratrol
  • Curcumin